tiprankstipranks
Trending News
More News >
Hyperfine (HYPR)
NASDAQ:HYPR
US Market

Hyperfine (HYPR) AI Stock Analysis

Compare
112 Followers

Top Page

HY

Hyperfine

(NASDAQ:HYPR)

46Neutral
Hyperfine's overall stock score reflects a company in transition, with strong revenue growth and a solid equity position but facing significant profitability challenges. While its strategic initiatives and technological advancements present growth opportunities, ongoing net losses and negative cash flows are significant concerns. The technical analysis indicates a neutral to bearish trend, while valuation metrics highlight financial struggles, making the stock less attractive to risk-averse investors.
Positive Factors
Financial Stability
Following the January restructuring, the company now estimates it has cash through 2026.
Market Expansion
The company is set to expand the total addressable market from $1.5 billion to over $6 billion with two new indications: Alzheimer’s and Stroke.
Product Development
HYPR is partnering with NVIDIA to develop future technologies that incorporate NVIDIA's advanced artificial intelligence (AI) capabilities with the Swoop system.
Negative Factors
Revenue Performance
Revenue of $2.1M missed both consensus and analysts' estimate by approximately $0.7M.
Sales Cycle
HYPR is seeing an elongation in their selling cycle of up to 18 months due to ongoing softness in the hospital capital environment.

Hyperfine (HYPR) vs. S&P 500 (SPY)

Hyperfine Business Overview & Revenue Model

Company DescriptionHyperfine (HYPR) is a pioneering medical technology company dedicated to transforming healthcare through its development of portable, affordable, and easy-to-use MRI systems. Operating within the medical imaging sector, Hyperfine's flagship product, the Swoop Portable MR Imaging System, is designed to provide real-time brain imaging at the point of care, enhancing diagnostic capabilities in diverse clinical settings including emergency departments, intensive care units, and rural or underserved areas.
How the Company Makes MoneyHyperfine makes money through the sale and leasing of its Swoop Portable MR Imaging System. The company's revenue model includes direct sales to hospitals and healthcare facilities, as well as leasing arrangements that provide a recurring revenue stream. Additionally, Hyperfine generates income from ongoing service and maintenance contracts, ensuring optimal performance and longevity of their imaging systems. Strategic partnerships with healthcare providers and collaborations with research institutions also contribute to its revenue, expanding its market reach and fostering innovation in portable medical imaging solutions.

Hyperfine Financial Statement Overview

Summary
While Hyperfine shows strong revenue growth and a solid equity position without debt, it continues to face profitability challenges with substantial net losses and negative cash flows. The high equity ratio is a strength, but ongoing operational inefficiencies and a negative ROE are major concerns.
Income Statement
30
Negative
Hyperfine's income statement shows significant revenue growth over the years, with the latest revenue of $12.89 million compared to $0.29 million in 2020. However, the company continues to operate at a loss, with a net loss of $40.72 million for 2024. The gross profit margin has improved to 45.7% in 2024 from a negative margin in earlier years, but net profit margins remain substantially negative. The EBIT and EBITDA margins are also deeply negative, indicating ongoing operational challenges. The revenue growth is a positive sign, but the persistent losses are a major concern.
Balance Sheet
55
Neutral
The balance sheet of Hyperfine shows a relatively strong equity position with stockholders' equity at $49.04 million by the end of 2024. The company has no debt, resulting in a debt-to-equity ratio of 0, which is a positive aspect. However, the return on equity is negative due to significant net losses. The equity ratio stands at 83.2%, indicating a strong capital structure. The absence of debt and a high equity ratio are strengths, yet the negative ROE reflects profitability challenges.
Cash Flow
40
Negative
Hyperfine's cash flow statement reveals negative free cash flow, with a free cash flow of -$39.15 million in 2024. Operating cash flow exceeds net income, suggesting decent cash conversion efficiency, but both metrics are negative. The company has been investing less over time, which may impact future growth prospects. While the company has managed to finance operations without debt, the continuous negative cash flows pose a risk to long-term sustainability.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
12.89M11.03M6.81M1.50M294.00K
Gross Profit
5.89M4.76M907.00K-1.17M-477.00K
EBIT
-43.22M-48.12M-73.87M-64.87M-23.49M
EBITDA
-42.22M-47.06M-72.86M-64.14M-23.20M
Net Income Common Stockholders
-40.72M-44.24M-72.45M-64.83M-23.36M
Balance SheetCash, Cash Equivalents and Short-Term Investments
37.65M75.18M117.47M188.50M62.68M
Total Assets
58.90M94.20M134.05M202.47M71.53M
Total Debt
269.00K185.00K0.000.00178.00K
Net Debt
-37.38M-75.00M-117.47M-188.50M-62.50M
Total Liabilities
9.86M9.80M10.33M16.25M132.58M
Stockholders Equity
49.04M84.40M123.72M186.23M-61.05M
Cash FlowFree Cash Flow
-39.15M-42.61M-72.92M-49.89M-23.09M
Operating Cash Flow
-38.77M-41.81M-72.34M-47.18M-21.52M
Investing Cash Flow
-383.00K-804.00K-585.00K-2.71M-1.57M
Financing Cash Flow
1.02M174.00K7.00K176.77M60.94M

Hyperfine Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.60
Price Trends
50DMA
0.77
Negative
100DMA
0.91
Negative
200DMA
0.96
Negative
Market Momentum
MACD
-0.03
Positive
RSI
34.57
Neutral
STOCH
14.35
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPR, the sentiment is Negative. The current price of 0.6 is below the 20-day moving average (MA) of 0.71, below the 50-day MA of 0.77, and below the 200-day MA of 0.96, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 34.57 is Neutral, neither overbought nor oversold. The STOCH value of 14.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HYPR.

Hyperfine Risk Analysis

Hyperfine disclosed 76 risk factors in its most recent earnings report. Hyperfine reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Hyperfine Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$107.86M-16.53%-4.15%3.49%
52
Neutral
$5.04B3.15-44.58%2.85%16.08%-0.27%
50
Neutral
$38.76M-267.29%12.78%15.53%
46
Neutral
$47.68M-67.86%0.34%6.20%
43
Neutral
$44.64M-505.14%-11.21%47.20%
KZKZR
42
Neutral
$30.17M-57.78%-100.00%18.17%
39
Underperform
$45.62M-104.36%-1455.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HYPR
Hyperfine
0.60
-0.29
-32.58%
ICAD
iCAD
3.92
2.17
124.00%
MRSN
Mersana Therapeutics
0.31
-2.42
-88.64%
KZR
Kezar Life Sciences
4.06
-3.60
-47.00%
TELA
TELA Bio
0.98
-5.30
-84.39%
RBOT
Vicarious Surgical
7.19
-5.48
-43.25%

Hyperfine Earnings Call Summary

Earnings Call Date:May 13, 2025
(Q1-2025)
|
% Change Since: -14.29%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call outlines a transitional period for Hyperfine, with significant focus on diversifying revenue streams and technological advancements. While there are promising growth opportunities in the office and international markets, challenges such as prolonged sales cycles, revenue headwinds from grant cancellations, and continued net losses suggest a cautious outlook.
Q1-2025 Updates
Positive Updates
Revenue and Financial Management
Revenue for Q1 2025 was $2.1 million with a strong average selling price. The company raised $6 million through a registered direct offering, extending the cash runway to the end of 2026.
Diversified Growth Strategy
Hyperfine is transitioning from a reliance on U.S. hospital deals to a diversified portfolio including hospitals, office settings, and international markets. The launch of the office business and improved technology are expected to drive growth in the second-half of 2025.
International Expansion
Strong interest and demand are seen across Europe, the Middle East, and Asia, with anticipated regulatory approval and market entrance in India in the second-half of the year.
Technological Advancements
The company is improving the image quality of their AI-powered portable MRI, with expected clearance for next-generation software and technology releases later in the year.
Negative Updates
Revenue Headwinds
Revenue was impacted by the loss of several deals at large academic institutions due to reductions and cancellations of grant funding.
Longer Sales Cycles
Sales cycles for U.S. hospitals are experiencing longer timelines, now estimated to be between 1 to 1.5 years.
Net Loss
Net loss for Q1 2025 was $9.4 million, slightly improved from $9.8 million in the prior year, equating to a net loss of $0.12 per share.
High Cash Burn
Net cash burn for Q1 2025 was $4.6 million, with a total cash burn excluding financing of $10.1 million, although this was down 16% from the previous year.
Company Guidance
During the Hyperfine Q1 2025 earnings call, the company provided guidance on their financial outlook and strategic initiatives. Revenue for the first quarter was reported at $2.1 million, with six systems sold and a strong average selling price. Hyperfine aims to diversify its revenue streams across hospitals, office settings, and international markets, with significant growth expected in the second half of 2025. The company anticipates revenue growth of 10% to 20% over the previous year, with a full-year gross margin outlook of 47% to 50%. Hyperfine also projects a total cash burn of $25 million to $28 million for the year, representing a 31% decline from 2024. The company is focused on expanding the adoption of its AI-powered portable MRI technology, with plans to launch in-office business mid-2025 and has made progress towards international expansion, notably anticipating regulatory approval in India.

Hyperfine Corporate Events

Product-Related AnnouncementsExecutive/Board ChangesBusiness Operations and Strategy
Hyperfine Achieves Key Milestones for 2025 Growth
Positive
Feb 11, 2025

In the fourth quarter of 2024, Hyperfine achieved several milestones to support its growth in 2025. These accomplishments include receiving accreditation for its ultra-low-field MRI technology from the Intersocietal Accreditation Commission, obtaining CE approval for its AI-powered brain imaging software, and expanding global market reach with new distribution partnerships. The company also presented scientific abstracts and data at notable conferences, highlighting the potential value of its Swoop® system in patient management and appointed new executives to drive its adoption in hospital and neurology office settings.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.